Compare SLI & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLI | PHAT |
|---|---|---|
| Founded | 1998 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 906.4M | 969.8M |
| IPO Year | 2011 | 2019 |
| Metric | SLI | PHAT |
|---|---|---|
| Price | $2.29 | $10.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $5.25 | ★ $19.83 |
| AVG Volume (30 Days) | ★ 1.9M | 1.2M |
| Earning Date | 05-11-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 42.72 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $175,110,000.00 |
| Revenue This Year | N/A | $93.04 |
| Revenue Next Year | N/A | $58.91 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 216.93 |
| 52 Week Low | $2.20 | $7.61 |
| 52 Week High | $6.40 | $18.31 |
| Indicator | SLI | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 24.12 | 48.04 |
| Support Level | N/A | $10.02 |
| Resistance Level | $4.38 | $11.65 |
| Average True Range (ATR) | 0.15 | 0.71 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 8.60 | 34.40 |
Standard Lithium Corp is engaged in the exploration and development of lithium brine properties in the United States. The company the company's flagship projects are located in the Smackover Formation, a world-class lithium brine asset, focused in Arkansas and Texas. It is also Standard Lithium is advancing the South West Arkansas project, a greenfield project located in southern Arkansas, and strengthening lithium brine prospects in East Texas. Its other project comprises the Lanxess Property Project; and California Properties. The technologies used for the projects are : Direct Lithium Extraction; Demonstration Plant; SiFT; Lithium Sulfide; and Aqualung.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.